Clinical Trial Update: Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating mobilization of stem cells with plerixafor (AMD3100) in patients with Non-Hodgkin lymphoma has completed and posted results in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Mozobil (plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: COMPLETED | Results posted: 2010-09-29